Journal for ImmunoTherapy of Cancer (Nov 2023)
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
- Monika Semmrich,
- Linda Mårtensson,
- Ingrid Teige,
- Björn Frendeus,
- Mathilda Kovacek,
- Petra Holmkvist,
- Carolin Svensson,
- Therese Blidberg,
- Andres McAllister,
- Marie Borggren,
- Ingrid Karlsson,
- Mark Cragg,
- Mimoza Bodén,
- Kirstie Cleary,
- Osman Dadas,
- Benjamin Duell,
- Jan Anders Nilsson,
- Stephen Beers,
- Sean Lim,
- Johan E Wallin
Affiliations
- Monika Semmrich
- 1BioInvent International, Lund, Sweden
- Linda Mårtensson
- 1BioInvent International, Lund, Sweden
- Ingrid Teige
- 1BioInvent International, Lund, Sweden
- Björn Frendeus
- 1BioInvent International, Lund, Sweden
- Mathilda Kovacek
- 1BioInvent International, Lund, Sweden
- Petra Holmkvist
- 1BioInvent International, Lund, Sweden
- Carolin Svensson
- 1BioInvent International, Lund, Sweden
- Therese Blidberg
- 1BioInvent International, Lund, Sweden
- Andres McAllister
- 1BioInvent International, Lund, Sweden
- Marie Borggren
- 1BioInvent International, Lund, Sweden
- Ingrid Karlsson
- 1BioInvent International, Lund, Sweden
- Mark Cragg
- 2University of Southampton, Southampton, UK
- Mimoza Bodén
- 1BioInvent International, Lund, Sweden
- Kirstie Cleary
- 2University of Southampton, Southampton, UK
- Osman Dadas
- 2University of Southampton, Southampton, UK
- Benjamin Duell
- 1BioInvent International, Lund, Sweden
- Jan Anders Nilsson
- 1BioInvent International, Lund, Sweden
- Stephen Beers
- 2University of Southampton, Southampton, UK
- Sean Lim
- 2University of Southampton, Southampton, UK
- Johan E Wallin
- 3BioInvent, Lund, Sweden
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.1368
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
